SEATTLE & CHICAGO--(BUSINESS WIRE)--Nativis, Inc., a clinical-stage life science bio-electronics company developing non-invasive treatments for cancers and other serious diseases and health care needs, and Kronus Innovations, LLC, a biotechnology research and development company headquartered in Chicago, with its research and development team in St. Louis, today announced that the two companies are entering into a collaborative evaluation agreement to explore the utilization of Nativis’ proprietary ultra-low Radio Frequency Energy (ulRFE) platform technology in several bio-agriculture applications. The goal of this evaluation agreement is to assess the potential utilization of ulRFE as a safe and enabling technology in bio-agriculture.
“We are extremely excited and encouraged by this evaluation agreement with Kronus Innovations,” stated Chris Rivera, President and CEO of Nativis. “We have completed several internal proof of concept in vitro assays in bio-agriculture. However, working with a company like Kronus, with their expertise in this area, will expand on these experiments and demonstrate the potential of ulRFE as a platform and enabling technology for numerous applications.”
During the course of the agreement, Nativis and Kronus will discuss a potential long-term strategic relationship to explore opportunities and applications for ulRFE in agriculture.
“Kronus is pleased to work with Nativis and their proprietary ulRFE technology,” stated Andy Daniels, Founder and CEO of Kronus Innovations. “We are thrilled to examine the potential that the ulRFE product platform has in agriculture and believe this technology may significantly change many aspects of our industry. We look forward to becoming the ulRFE leader in agriculture and delivering significant improvements and cost-effective benefits to our customers.”
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.
About Kronus Innovations
Kronus Innovations is an early stage, intellectual property development and commercialization company creating tailored applications of ultra-low RFE (ulRFE) technology for agricultural use. At the interface of chemistry, biology and physics, Kronus intends to increase productivity of crops by enhancing the performance of seeds, reducing artificial inputs in livestock, and optimizing nutrition in aquaculture.
Nandi (Thorn) Butcher, 206-343-1543
Investor Relations Contact:
Lee Roth/Tram Bui
email@example.com / firstname.lastname@example.org
Bia Thomas, PhD
Investor Relations Contact:
Duke Leahey, 314-956-1279
Last updated on: 13/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.